AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial
Amgen and Kyowa Kirin’s rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks […]